Glioblastoma — frontier options in Minnesota
30 open options
- TRIALPHASE1 / PHASE2RECRUITING
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Biospecimen Collection · Eflornithine · Lumbar Puncture — 1 site
- TRIALPHASE2RECRUITING
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Temozolomide · Neratinib · QBS10072S — 12 sites
- TRIALPHASE1 / PHASE2RECRUITING
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
TNG456 · abemaciclib — 15 sites
- TRIALPHASE2RECRUITING
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Bevacizumab · Biospecimen Collection · Computed Tomography — 3 sites
- TRIALNANOT_YET_RECRUITING
A Study for Cerebral Open Flow Microperfusion
Cerebral open flow microperfusion — 1 site
- TRIALPHASE2NOT_YET_RECRUITING
Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma
Archive Sample Retrieval · Biospecimen Collection · Chest Radiography — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Biopsy Procedure · Magnetic Resonance Imaging · Radiation Therapy — 127 sites
- TRIALPHASE1RECRUITING
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
Everolimus · Trametinib — 17 sites
- TRIALPHASE3RECRUITING
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
SonoCloud-9 (SC9) · Carboplatin · Lomustine — 55 sites
- TRIALNARECRUITING
Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma
Best Practice · Biospecimen Collection · Dietary Intervention — 3 sites
- TRIALPHASE1RECRUITING
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
Treatment with CD200AR-L — 1 site
- TRIALPHASE1RECRUITING
ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma
WSD0628 — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
APG-157 — 2 sites
- TRIALPHASE2RECRUITING
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
5-ALA HCl + LIDU SDT · Placebo + Sham SDT — 11 sites
- TRIALEARLY_PHASE1RECRUITING
Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
Biospecimen Collection · Computed Tomography · Eflornithine — 1 site
- EXPANDED ACCESSAVAILABLE
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Ulixertinib (BVD-523) — 26 sites
- TRIALPHASE2NOT_YET_RECRUITING
Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas
NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy · Cemiplimab · Chemotherapy — 2 sites
- TRIALPHASE1 / PHASE2RECRUITING
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Biospecimen Collection · Magnetic Resonance Imaging · Placebo Administration — 36 sites
- TRIALPHASE1RECRUITING
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103 — 4 sites
- TRIALPHASE2RECRUITING
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
BMS-986504 · Daraxonrasib · Nivolumab + Relatlimab FDC — 57 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
MT-125 — 3 sites
- TRIALNARECRUITING
Feasibility of Intra- and Post-operative Microdialysis During Neurosurgery for Central Nervous System Lesions
Microdialysis · Magnetic Resonance Imaging · Computed Tomography — 1 site
- TRIALEARLY_PHASE1RECRUITING
Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma
Aminolevulinic Acid Intravenous Formulation SONALA-001 · Biospecimen Collection · Computed Tomography — 1 site
- TRIALPHASE2RECRUITING
An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma
Computed Tomography · Electronic Health Record Review · Ga 68 PSMA-11 — 1 site
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma
MT-125 — 3 sites
- TRIALPHASE3RECRUITING
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Optune® device · Temozolomide · Pembrolizumab — 102 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Temozolomide · Lomustine · Regorafenib — 63 sites
- EXPANDED ACCESSAVAILABLE
Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
DCVax-L — 27 sites
- TRIALPHASE1RECRUITING
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
PF-07799544 · PF-07799933 — 83 sites
- TRIALPHASE3RECRUITING
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
safusidenib · Placebo — 57 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.